

# the **ADBL** report

Issue #120, May 2021

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

## EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Acting Chair)  
Caitlin A. Clarke, BScPhm, PharmD  
Margaret Gray, BSP, FCSHP  
Michael Kolber, BSc, MD, CCFP, MSc  
Naeem Ladhani, BScPharm  
Tony Nickonchuk, BScPharm  
Glen J. Pearson, BScPhm, PharmD, FCSHP, FCCS  
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

## ALBERTA HEALTH LIAISON:

Chad Mitchell, BSc Pharm, MSc

## ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)  
Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA

## In this issue:

- **Brief Summary of Drug Review Activities**
- **Highlights of:**
  - ❖ **Products Originally Reviewed via the CDR**
  - ❖ **Interchangeable Drug Products Added**
  - ❖ **Biosimilar Drug Products Added**
  - ❖ **Drug Products Added**
- **Special Authorization Criteria Changes**
- **Delisted Products**

## Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on March 16, 2021. The Committee reviewed Manufacturer submissions for thirteen (13) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a supplementary assessment of the coverage status of one (1) Drug Product.

In addition to Drug Products reviewed by the Expert Committee, fifty-seven (57) Drug Products underwent Expedited Review for listing on the ADBL effective May 1, 2021.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.php>

## Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL effective April 1, 2021:

- **AERMONY RESPICLICK 55 mcg/dose, 113 mcg/dose & 232 mcg/dose metered inhalation powders** (fluticasone propionate) (TEV)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL effective May 1, 2021:

- **MONOFERRIC\* 100 mg/mL injection** (iron isomaltoside 1000) (PFI) via Special Authorization (SA)
- **REVESTIVE\* 5 mg/vial injection** (teduglutide) (TAK) via SA for the indication of Pediatric Short Bowel Syndrome
- **VYNDAQEL\* 20 mg capsule** (tafamidis meglumine) (PFI) via SA

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\*

ABC81171 (05/2021)

## ***Highlights of Interchangeable (IC) Drug Products Added***

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective May 1, 2021:

- **TEVA-BETAMETHASONE/CALCIPOTRIOL 50 mcg/g / 0.5 mg/g topical ointment** (calcipotriol monohydrate/betamethasone dipropionate) (TEV)

## ***Highlights of Biosimilar Drug Products Added***

The following Biosimilar Drug Products were added to the *ADBL* effective May 1, 2021:

- **AMGEVITA\* 40 mg/0.8 mL prefilled syringe & autoinjector** (adalimumab) (AMG) via SA for the indications of Rheumatoid Arthritis (RA), Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Crohn's Disease (CD), Ulcerative Colitis (UC), and Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- **AMGEVITA\* 20 mg/0.4 mL prefilled syringe** (adalimumab) (AMG) via SA for the indication pJIA
- **HADLIMA\* 40 mg/0.8 mL autoinjector & injection syringe** (adalimumab) (SSB) via SA for the indications of RA, PsO, PsA, AS, HS, CD, UC & pJIA
- **HULIO\* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (BGP) via SA for the indications of RA, PsO, PsA, AS, HS, CD, UC & pJIA
- **HYRIMOZ\* 40 mg/0.8 mL injection pen & syringe** (adalimumab) (SDZ) via SA for the indications of RA, PsO, PsA, AS, HS, CD, UC & pJIA
- **HYRIMOZ\* 20 mg/0.4 mL injection syringe** (adalimumab) (SDZ) via SA for the indication of pJIA
- **IDACIO\* 40 mg/0.8 mL injection pen** (adalimumab) (FKC) via SA for the indications of RA, PsO, PsA, AS, HS, CD, UC & pJIA
- **NYVEPRIA\* 6 mg/0.6 mL injection syringe** (pegfilgrastim) (PFI) via SA

## ***Highlights of Drug Products Added***

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective April 1, 2021:

- **ACTEMRA\* 162 mg/0.9 mL auto injector** (tocilizumab) (HLR) via SA for the indications of Giant Cell Arteritis (GCA), pJIA & Systemic Juvenile Idiopathic Arthritis (sJIA)

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective May 1, 2021:

- **CREON 35 MINIMICROSPHERES 35,000 unit/ 35,700 unit/ 2,240 unit capsule** (lipase/amylase/protease) (BGP)
- **FASENRA\* 30 mg/mL injection pen** (benralizumab) (AZC) via SA
- **TAKHZYRO\* 150 mg/mL injection syringe** (lanadelumab) (SHB) via SA

## ***Special Authorization Criteria Changes***

The Special Authorization criteria for coverage for the following Drug Products have been revised effective May 1, 2021:

- **BRENZYS\* 50 mg/mL auto injector & injection syringe** (etanercept) (SSB) for the indications of PsO & pJIA
- **ERELZI\* 25 mg/0.5 mL & 50 mg/mL injection syringes and 50 mg/mL sensoready auto injector syringe** (etanercept) (SDZ) for the indications of PsO & pJIA
- **ENBREL\* 25 mg/vial injection** (etanercept) (AMG) for the indications of PsO & pJIA
- **HUMIRA\* 20 mg/0.2 mL and 40 mg/0.8 mL injection syringes** (adalimumab) (ABV)
- **PROCYSBI\* 25 mg & 75 mg delayed-release capsules** (cysteamine bitartrate) (RAP)

## ***Delisted Products***

The following Drug Product was delisted from the *ADBL* effective May 1, 2021 due to the Alberta Biosimilar Initiative:

- **ENBREL 50 mg/mL injection syringe** (etanercept) (AMG)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*